The price of AVAH is predicted to go up 4.62%, based on the high correlation periods with HBB. The similarity of these two price pattern on the periods is 90.87%.
AVAH
HBB
Up: 4.62%Similarity: 90.87%
AVAH Revenue Forecast
AVAH EPS Forecast
AVAH FAQs
What is bull’s view on AVAH?
Aveanna Healthcare Holdings Inc. (AVAH) is currently trading at $4.62, down 4.17% from the previous close. The stock has a Zacks Rank #1 (Strong Buy), supported by a 40% increase in earnings estimates over the past 60 days, indicating strong growth potential. Analysts have set a price target of $5.25, reflecting a 15.51% upside, driven by favorable sector tailwinds and improved cash flow generation.
What is bear's view on AVAH?
Aveanna Healthcare Holdings Inc. (AVAH) is currently viewed positively by analysts, with a Zacks Rank #1 (Strong Buy). The stock has shown a significant increase in earnings estimates, up 40% over the past 60 days, and is trading near a Fibonacci pivot of $4.80. However, its RSI of 43.50 suggests it is not yet overbought, leaving room for potential upside.
What is AVAH revenue forecast for next quarter?
The market consensus for AVAH's revenue in the upcoming quarter is projected to be approximately $516.172M USD.
What is AVAH eps forecast for next quarter?
The market consensus for AVAH's eps in the upcoming quarter is projected to be approximately $0.003 USD.
Truist analyst David MacDonald lowered the firm's price target on Aveanna to $5.25 from $6 and keeps a Hold rating on the shares as part of a broader research note previewing 2025 for Healthcare Services. The firm sees the outlook for the group as "mixed", with bullish stance on the underlying demand drivers and overarching sector tailwinds that include demographics, value-based care, and core demand being offset by heightened concern around a likely more cost focused government backdrop. Selectivity is key and cash flow generation with broadly attractive financial flexibility are set to provide solid support, while the recent valuation re-rating for several names provides a better setup around risk/reward, the analyst tells investors in a research note.